NEWS

Alzheimer's disease is an important cause of dementia, which is characterized by memory loss, cognitive impairment and personality changes, and seriously threatens the lifespan and quality of life of the elderly, experts said. With the deepening of population aging, the number of patients with Alzheimer's disease is increasing, but there are only a few drugs for clinical treatment of Alzheimer's disease, which is far from meeting the needs of the majority of patients.

Current studies suggest that amyloid plaques formed by deposition of amyloid -β (Aβ) in the brain are the most significant pathological feature and pathogenesis of Alzheimer's disease. Therefore, Aβ has become the most important target for drugs to treat Alzheimer's disease. However, developing A compound that can both recognize Aβ and inhibit and eliminate amyloid plaques is currently A major challenge in Alzheimer's disease drug development. Therefore, we applied the concept of heteropoly coassembly to the treatment of Alzheimer's disease for the first time. According to the amino acid sequence of Aβ, we designed A coassembly composed of cyclodextrin and calixarene, and discussed the application prospect of this nanomaterial in the treatment of alzheimer's disease.

The team found that the co-assembler showed A good ability to depolymerize Aβ fibers and prevent nerve cell death. In animal studies, coassembler was found to reduce the levels of different forms of Aβ (plaques, oligomers, and monomers) in the brain of mouse models of Alzheimer's disease. What's more, the coassembler significantly improved cognitive impairment, oxidative stress, neuronal death and neuroinflammation in alzheimer's disease model mice.

In recent years, specific clearance of Aβ has become A hot spot in the drug development of Alzheimer's disease. The cyclodextrin-calixarene coassembly is expected to be A potential drug for the treatment of Alzheimer's disease in view of its strong binding ability to Aβ, good improvement of cognitive ability and low toxicity, bringing new hope to the majority of patients and their families.